Elucidation of Immune Evasion Mechanisms of Staphylococcus aureus Biofilms and Multifaceted Anti-Biofilm Therapeutic Strategies
Background
Among pathogens, Staphylococcus aureus (hereafter S. aureus) is a representative pathogen that causes various infections in both community and healthcare settings. The formation of biofilms is a key factor in the chronicity and recurrence of infections caused by this bacterium. When bacteria adhere to a specific surface, form clusters, and are surrounded by a structure composed of extracellular polymeric substances (hereafter ECM) secreted by themselves, it becomes extremely difficult to control them with existing treatment methods.
Conventional antibiotic prescriptions have focused on killing free-floating bacteria. However, when a protective ECM layer is formed, the physical penetration of drugs is blocked. Immune cells also struggle to access the interior of the structure, making it difficult to effectively clear the infection site. These limitations are particularly severe on the surfaces of medical devices such as catheters and artificial joints implanted in the patient's body, ultimately leading to chronic and recurrent infections. The medical field urgently requires a new therapeutic paradigm to break down this robust structure.
Key Findings
The development of S. aureus biofilms involves a highly organized process intertwined with genetic regulators, environmental factors, and quorum sensing (hereafter QS) signaling systems. This analysis revealed that when biofilms form, significant changes occur at both physiological and transcriptomic and proteomic levels within the bacterial population. These changes act as defense mechanisms that maximize bacterial survival in harsh host environments.
Antimicrobial resistance within biofilms is manifested through multiple complementary mechanisms. First, in addition to reduced drug penetration, the overall physiological activity of the bacteria is lowered, resulting in a sharp decrease in antibiotic susceptibility. Second, it has been proven that metabolically dormant persister cells, which survive antibiotic attacks without dying, contribute to maintaining survival rates. Finally, the activation of stress response pathways and the presence of polymicrobial biofilm environments with coexisting heterogeneous microorganisms further reinforce resistance. Host-biofilm interactions that disrupt the host's immune response and induce abnormal inflammatory reactions have also been identified as key factors in the establishment of chronic infections.
Significance and Prospects
Mature biofilms cannot be fundamentally resolved with traditional chemotherapeutic agents alone. As a result, recent academic and industrial efforts have focused on developing matrix-degrading agents and QS inhibitors that directly break down the ECM structure. Multifaceted candidate substances, including antimicrobial peptides, bacteriophage-based biological agents, nanoparticle-assisted targeted delivery systems, and CRISPR-Cas-based therapeutics, are receiving significant attention. Their combination therapies are emerging as alternatives that dismantle the biofilm's defense barrier, expose the bacteria, and restore the efficacy of existing antibiotics.
However, there are numerous challenges to be addressed before these next-generation therapies can be applied clinically. The in vivo safety of nano-delivery systems and the control of host immune responses upon bacteriophage administration are primary obstacles. Thorough verification of potential toxicity and drug interactions when combining drugs with different mechanisms of action is also essential. To advance biofilm control technology beyond the laboratory and into practical application, evaluation of efficacy in animal models and large-scale clinical studies are indispensable.
S. aureus is a significant opportunistic pathogen that causes a variety of community and healthcare-associated infections. Biofilm formation is one of its many virulence factors and contributes to persistent, recurrent, and device-associated infections through enhancing bacterial survival, immune system evasion, and resistance to antimicrobial agents. The development of biofilms is a complex, highly regulated process influenced by genetic regulators, environmental factors, and intercellular communication, leading to the formation of a structured microbial community with a protective extracellular matrix (ECM). These biofilms undergo large-scale physiological, transcriptomic, and proteomic changes, which help them survive harsh host conditions and reduce their susceptibility to immune responses and standard antibiotics. Biofilm-associated antimicrobial resistance is also facilitated by several complementary mechanisms, including limited penetration of antimicrobials, changes in bacterial physiology, persister cell formation, adaptive stress responses, and the presence of other clinically relevant microorganisms in polymicrobial biofilms. Recent evidence has also emphasized the importance of host-biofilm interactions in the establishment of chronic infections, including dysregulated inflammatory responses and immune evasion. Due to the intrinsic inefficacy of traditional antimicrobial drug treatment against mature biofilms, significant efforts have been made to develop novel anti-biofilm interventions, such as matrix-disrupting agents, quorum-sensing inhibitors, antimicrobial peptides, bacteriophages, nanotechnology-assisted delivery systems, CRISPR-Cas-based therapeutics, and rational combination therapy. This review aims to provide a comprehensive and up-to-date overview of the molecular biology of S. aureus biofilms, biofilm-associated antimicrobial resistance, interactions with the host, polymicrobial interactions, and emerging therapeutic strategies, and to highl
The anti-biofilm therapeutic strategies presented in this study provide a breakthrough for significantly reducing the cost and duration of treatment for patients with medical device-related infections, such as those involving artificial joints or vascular catheters. Specifically, a scenario is possible in which nanocoating technology is applied to surgical sites, combining matrix-degrading enzymes and antibiotics to prevent biofilm formation from the initial bacterial attachment stage. For patients with refractory traumatic infections, a clinical pathway could be developed by combining bacteriophages and CRISPR-based therapeutics to selectively eliminate antibiotic-resistant superbugs, thereby preventing severe complications such as amputation.